186 related articles for article (PubMed ID: 21771101)
1. Immunohistochemical biomarkers for bladder cancer prognosis.
Matsushita K; Cha EK; Matsumoto K; Baba S; Chromecki TF; Fajkovic H; Sun M; Karakiewicz PI; Scherr DS; Shariat SF
Int J Urol; 2011 Sep; 18(9):616-29. PubMed ID: 21771101
[TBL] [Abstract][Full Text] [Related]
2. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
3. Current status of molecular markers for prognostication and outcome in invasive bladder cancer.
Gakis G; Schwentner C; Todenhöfer T; Stenzl A
BJU Int; 2012 Jul; 110(2):233-7. PubMed ID: 22233187
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
5. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
[TBL] [Abstract][Full Text] [Related]
6. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
7. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.
Youssef RF; Shariat SF; Kapur P; Kabbani W; Ghoneim T; King E; Cockburn A; Mosbah A; Abol-Enein H; Ghoneim M; Lotan Y
Hum Pathol; 2011 Mar; 42(3):347-55. PubMed ID: 21111452
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
9. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
[TBL] [Abstract][Full Text] [Related]
10. Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers.
Kapur P; Lotan Y; King E; Kabbani W; Mitra AP; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
Am J Clin Pathol; 2011 Jun; 135(6):822-30. PubMed ID: 21571954
[TBL] [Abstract][Full Text] [Related]
11. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
13. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
[TBL] [Abstract][Full Text] [Related]
14. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
15. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
16. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder.
Xylinas E; Kluth LA; Lotan Y; Daneshmand S; Rieken M; Karakiewicz PI; Shariat SF
Urol Oncol; 2014 Apr; 32(3):230-42. PubMed ID: 24332648
[TBL] [Abstract][Full Text] [Related]
17. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use.
Bolenz C; Lotan Y
Nat Clin Pract Urol; 2008 Dec; 5(12):676-85. PubMed ID: 19050710
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
